

# HBV Immunizations

This is a PDF version of the following document:

Module 3: [Prevention of HBV](#)

Lesson 1: [HBV Immunizations](#)

You can always find the most up-to-date version of this document at

<https://www.hepatitisB.uw.edu/go/prevention-hbv/hbv-immunizations/core-concept/all>.

---

## Background

Vaccination is the mainstay of hepatitis B virus (HBV) prevention and represents a core intervention in the World Health Organization's (WHO) efforts to eliminate hepatitis B by 2030.[1] Following the licensure of the first hepatitis B vaccine in 1981, there have been major advances in hepatitis B vaccines. In addition, vaccine recommendations have evolved over the past several decades, culminating in the recommendation for universal hepatitis B immunization for all persons younger than 60 years of age.[2] The following briefly summarizes the chronology and type of hepatitis B vaccines licensed for use in the United States ([Figure 1](#)).

- The first hepatitis B vaccine, which was plasma-derived, was licensed in the United States in 1981.[3] This vaccine contained purified plasma-derived hepatitis B surface antigen (HBsAg) and was safe and highly successful in preventing HBV infection.[3,4,5] Nevertheless, the first-generation plasma-derived HBV vaccine was tedious to manufacture, and the plasma-derived vaccine led to unsubstantiated concerns regarding the potential for bloodborne pathogen transmission and was eventually discontinued in 1992.[3]
- By the mid-1980s, the second generation of hepatitis B vaccines became commercially available—Recombivax-HB and Engerix-B. These vaccines utilized recombinant DNA technology to express a nonglycosylated hepatitis B surface antigen in yeast cells, a process that was more cost-effective and scalable than the plasma-derived method.[3,4] Furthermore, yeast-derived vaccines eliminate any concern for vaccine-related bloodborne pathogen transmission.[3]
- In the 1990s, mammalian cell-derived HBV vaccines became commercially available. These vaccines contain both the S antigen and either the pre-S2 or the pre-S2 and pre-S1 HBV antigens. Although studies suggested these vaccines were efficacious in conventional HBV vaccine nonresponders and overall more immunogenic than yeast-derived recombinant vaccines, manufacturing costs were higher, and they were not widely used.[6]
- In 2017, the hepatitis B vaccine, Heplisav-B, was approved by the Food and Drug Administration (FDA). Heplisav-B contains a yeast-derived recombinant HBsAg as well as a novel cytidine-phosphate-guanosine oligodeoxynucleotide (Cpg ODN) adjuvant that binds toll-like receptor 9 and stimulates a more robust immune response to HBsAg than the historical alum adjuvant.[7] The Heplisav B vaccine is recommended for use in adults aged 18 years of age and older and represents the fifth inactivated HBV vaccine recommended in the United States.[7]
- Between 2021 and 2024 a tri-antigenic HBV vaccine known as PreHevrio was briefly on the market.[2] Despite proven efficacy, this vaccine was voluntarily taken off the market in 2024 due to bankruptcy of the manufacturing pharmaceutical company.

## Vaccine Uptake

Although acceptance of vaccine is high among adults offered hepatitis B vaccination, hepatitis B vaccine coverage is low. The National Health Interview Survey (NHIS) survey conducted during August 2017-June 2018 estimated a hepatitis B vaccine coverage of 30% for adults 19 years of age and older during the year 2018.[8] In this survey, the vaccine coverage varied by age—younger adults 19-49 years of age had a 40% hepatitis B vaccine coverage rate compared with only 19% for those 50 years of age and older.[8] From 2010-2018, hepatitis B vaccine coverage among adults 19 years of age and older has increased (range 24.5%-30.0%) (Figure 2).[8] In an earlier survey of men who have sex with men (MSM) surveyed in the Young Men's Health Study, only 17% had received a hepatitis B vaccine series, despite more than 90% of HBV-susceptible MSM in this study reporting access to health care services, including testing for HIV and other sexually transmitted infections.[9] The low rate of HBV immunization in these instances represents missed opportunities to provide vaccination to adults and highlights the need for increased HBV education in primary care regarding recent simplified universal vaccination guidance.[2]

## Indications for Hepatitis B Vaccination

Beginning in 1982, the Centers for Disease Control (CDC) and the Advisory Committee on Immunization Practices (ACIP) issued recommendations for hepatitis B vaccine for groups at risk of acquiring HBV, with recommendations subsequently expanding incrementally to include more groups for whom routine hepatitis B vaccine is indicated ([Figure 3](#)).<sup>[2,10,11,12,13,14]</sup> In 2022, the ACIP issued updated recommendations for hepatitis B vaccinations that called for universal hepatitis B vaccine in adults aged 19-59 years of age.<sup>[2]</sup> Based on these new recommendations, in the United States, hepatitis B vaccination is now recommended for all infants, all unvaccinated children and adolescents younger than age 19, all unvaccinated adults 19 to 59 years of age, and all adults 60 years of age and older with risk factors for HBV acquisition ([Table 1](#)).<sup>[2]</sup> The following summarizes the most recent and current ACIP hepatitis B vaccine recommendations in more detail.<sup>[2]</sup>

- **Infants:** All infants should receive the hepatitis B vaccine series as part of the routine childhood immunization schedule. The number of hepatitis B vaccine doses and the exact timing of vaccination differ slightly depending on the infant's birth weight, the maternal HBsAg status, and the vaccine used. For more detailed information, see [Preventing HBV Perinatal Transmission](#).
- **Children Younger than 19 Years of Age:** Children and adolescents who have not previously received the hepatitis B vaccine should be vaccinated as part of routine "catch-up vaccination," regardless of age.
- **Adults 19 to 59 Years of Age:** All adults 19 to 59 years of age should receive the hepatitis B vaccine. Adults who previously completed a hepatitis B vaccine series do not need additional hepatitis B vaccination. Persons with a history of HBV infection and those with active hepatitis B infection should not receive hepatitis B vaccination.
- **Adults 60 years of Age and Older with Risk Factors for HBV:** Adults 60 years of age and older, who have not completed the hepatitis B vaccine series and have no history of HBV infection, should be vaccinated against HBV if they are among any of the following groups:
  - **Persons at Risk for HBV infection by Sexual Exposure:** Sexual exposure is a well-defined risk factor for HBV acquisition and is likely responsible for more than 30% of incident HBV infections in the United States.<sup>[15]</sup> The following summarizes groups that should receive hepatitis B vaccine due to the risk of HBV acquisition from sexual exposure:
    - Sex partners of HBsAg-positive persons
    - Sexually active persons who are not in a long-term, mutually monogamous relationship (e.g., persons with more than one sex partner during the previous 6 months)
    - Persons seeking evaluation or treatment for a sexually transmitted infection
    - Men who have sex with men
  - **Persons at Risk for Infection by Percutaneous Exposure:** Percutaneous exposure is one of the most common risk factors for HBV acquisition in the United States, mainly due to the recent rise in injection drug use.<sup>[15,16,17]</sup> There are, however, several other groups, including health care workers, persons in long-term care facilities, and persons living with someone known to be HBsAg-positive, also known to be at risk for HBV via percutaneous exposure. The following summarizes persons who should receive the hepatitis B vaccine due to risk of percutaneous or mucosal exposure:
    - Persons who currently or recently injected drugs
    - Household contacts of HBsAg-positive persons
    - Residents and staff of facilities for developmentally disabled persons
    - Health care and public safety personnel with reasonably anticipated risk for exposure to blood or blood-contaminated body fluids
    - Hemodialysis, predialysis, peritoneal dialysis, and home dialysis patients
    - Persons with diabetes 60 years of age and older at the discretion of the treating clinician
  - **Others at Increased Risk of Acquiring HBV Infection**
    - International travelers to countries with high or intermediate levels of endemic HBV

infection, as defined by HBsAg prevalence of 2% or greater ([Table 2](#))

- Persons with hepatitis C virus infection
  - Persons with chronic liver disease (including, but not limited to, persons with cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, and an alanine aminotransferase [ALT] or aspartate aminotransferase [AST] level greater than twice the upper limit of normal)
  - Persons with HIV infection
  - Incarcerated persons
- **Adults 60 Years of Age and Older without Risk Factors:** Adults 60 years of age and older without known risk factors for HBV may receive the hepatitis B vaccine.

## Prevaccination Serologic Testing

### Potential Role of Prevaccination Serologic Testing

Prevaccination serologic testing has two potential roles: to identify persons with existing immunity to HBV who do not require vaccination and to detect persons with chronic active HBV.[13] If hepatitis B vaccination is administered to persons who are already immune to HBV (or chronically infected with HBV), it does not increase the risk for vaccine-related adverse events.[12] In general, routine prevaccination serologic testing is not recommended in settings where background immunity to hepatitis B is low, as it is not cost-effective.[13,18,19,20] In populations with a high HBsAg prevalence or with a high risk for chronic HBV, prevaccination serologic testing may reduce costs by avoiding unnecessary vaccinations. In these settings, prevaccination serologic testing also offers the opportunity to identify persons with chronic HBV infection and link them to care for management of chronic HBV infection.[2]

### Persons Recommended for Prevaccination Serologic Testing

Prevaccination serologic screening for hepatitis B should include the groups listed below but note that lack of access to prevaccination testing should not be a barrier to vaccination.[2,13]

- Household, sexual, or needle contacts of hepatitis B surface antigen (HBsAg)-positive persons
- Persons with HIV infection
- Persons with elevated alanine aminotransferase/aspartate aminotransferase of unknown etiology
- Hemodialysis patients
- Men who have sex with men
- Persons who inject drugs (past or present)
- Persons born in countries of high and intermediate hepatitis B virus (HBV) endemicity (HBsAg prevalence  $\geq 2\%$ )
- United States-born persons not vaccinated as infants whose parents were born in countries with high HBV endemicity ( $\geq 8\%$ )
- Persons needing immunosuppressive therapy, including chemotherapy, immunosuppression related to organ transplantation, and immunosuppression for rheumatologic or gastroenterologic disorders
- Donors of blood, plasma, organs, tissues, or semen

### Recommended Prevaccination Serologic Tests

If hepatitis B prevaccination serologic testing is performed, the CDC guidance recommends obtaining the following tests:[2,13]

- Hepatitis B surface antigen (HBsAg), *and*
- Antibody to HBsAg (anti-HBs), *and*
- Antibody to hepatitis B core antigen (anti-HBc).

### Serologic Testing and Timing of Hepatitis B Vaccination

Prevaccination serologic testing should not be a barrier to vaccination of persons potentially susceptible to HBV infection, especially hard-to-reach populations.[2,13] If prevaccination serologic testing is indicated, the first dose of hepatitis B vaccine can be delivered at the time blood is collected for serologic testing; if the serologic testing shows the person is immune or has HBV infection, then no further doses of the vaccine should be given. In venues where hepatitis B vaccination is recommended and serologic testing is not feasible, hepatitis B vaccination should simply be provided.[2,12,13,21]

## HBV Vaccines and Schedules

### HBV Vaccines Approved for Use in the United States

There are currently three single-antigen hepatitis B vaccines approved for use in the United States: Engerix-B, Recombivax HB, and Heplisav-B.[7,13] There are three FDA-approved combination vaccines that provide hepatitis B immunization in conjunction with other antigens; these include Twinrix (hepatitis A and B combination vaccine), Pediarix (hepatitis B, diphtheria-tetanus-acellular pertussis [DTaP]), and inactivated polio combination vaccine), and Vaxelis (hepatitis B, DTaP, inactivated poliovirus, and *Haemophilus influenzae*).[13] All of these vaccines utilize recombinant DNA technology to generate purified HBsAg as the hepatitis B vaccine antigen, and these vaccines, therefore, pose no risk for HBV transmission or transmission of other bloodborne viruses.[22] In the United States, none of the hepatitis B vaccines contain thimerosal (or they contain only trace amounts from the manufacturing process). The following provides a brief summary of each of these vaccines.

#### Single-Antigen Vaccines

- **Engerix-B:** This single-antigen hepatitis B vaccine contains yeast-derived (recombinant) HBsAg combined with an aluminum adjuvant. It is FDA-approved for use in individuals of all ages.
- **Heplisav-B:** This single-antigen hepatitis B recombinant vaccine consists of recombinant HBsAg combined with the synthetic immunostimulatory cytidine-phosphate-guanosine (CpG) oligodeoxynucleotide 1018 adjuvant; the CpG adjuvant binds to Toll-like receptor 9, signaling an innate immune system pathway in response to the HBsAg antigen. This vaccine is FDA-approved as a 2-dose series for use in persons 18 years of age and older.
- **Recombivax-HB:** This single-antigen hepatitis B vaccine contains recombinant HBsAg that is also produced in yeast cells and is combined with an aluminum adjuvant; this vaccine is FDA-approved for use in individuals of all ages.

#### Combination Vaccines

- **Twinrix:** This bivalent vaccine contains inactivated hepatitis A virus and recombinant HBsAg. Each 1 mL dose contains a lower quantity (720 ELISA units) of hepatitis A vaccine than the standard 1 mL single-antigen hepatitis A vaccine (1440 ELISA units). This vaccine is FDA-approved for use only in persons 18 years of age and older.
- **Pediarix:** This combination vaccine contains diphtheria toxoid, tetanus toxoid, acellular pertussis antigens, recombinant HBsAg, and inactivated poliovirus. This vaccine is FDA-approved as a 3-dose series in infants born of hepatitis B surface antigen (HBsAg)-negative mothers; this vaccine may be given as early as 6 weeks of age and through 6 years of age (prior to the seventh birthday). This vaccine is not approved for children younger than 6 weeks of life and thus should not be given for the birth-dose vaccination for HBV postexposure prophylaxis.
- **Vaxelis:** This combination vaccine contains diphtheria toxoid, tetanus toxoid, acellular pertussis antigens, inactivated poliovirus, recombinant HBsAg, and *Haemophilus influenzae* type b. This vaccine is FDA-approved as a 3-dose series in children 6 weeks through 4 years of age (prior to the fifth birthday). Although this vaccine is FDA-approved, it is not widely available. Accordingly, it will not be discussed further.

### Vaccine Dosing Schedules and Administration

Adults and children have distinct recommended hepatitis B vaccines and recommended vaccine schedules as outlined in (Figure 4) for adults and (Figure 5) for children.[13] The vaccine schedules for infants depend on birth weight and maternal HBsAg status (Table 3).[7,13] The amount of HBsAg and volume administered with each vaccine dose varies significantly based on age, which vaccine is used, and whether the individual is receiving hemodialysis (Table 4).[7,13]. All hepatitis B vaccines should be administered as intramuscular (IM)

injections, with the deltoid muscle the preferred site for adults, adolescents, and children. For infants less than 1 year of age, the anterolateral thigh should be used for intramuscular injection. Administration of hepatitis B vaccine in the buttocks or administration subcutaneously is not recommended for any of the FDA-approved hepatitis B vaccines, as administration by these routes is associated with lower levels of protective immune response.[23,24] At any age, subcutaneous administration is only recommended if intramuscular injection is not an option, such as in persons with hemophilia who have a significant risk of hemorrhage with intramuscular injection. The hepatitis B vaccine should not be given to any person with a history of a serious allergic response to a prior dose of hepatitis B vaccine, a component of the hepatitis B vaccine, or yeast.

## Choice of HBV Vaccine in Adults

In adults, the ACIP does not preferentially indicate which single-antigen hepatitis B vaccine to use. The ACIP recommends any of the following hepatitis B vaccines are safe to administer during pregnancy: Engerix-B, Heplisav-B, Recombivax HB, and Twinrix.[25] In general, the single-antigen hepatitis B vaccines—Engerix-B and Recombivax-HB—can be used interchangeably in adults.[13] For adults, if a 2-dose series is desired, Heplisav-B is the only option, as all other single-antigen vaccines require three doses.[7,13] In addition, a 2-dose hepatitis B vaccine series with Recombivax-HB can be used for adolescents 11 through 15 years of age who receive the adult-strength dose.[7,11,13] If adults require protection against both hepatitis A virus (HAV) and HBV, then Twinrix (combination hepatitis A and hepatitis B vaccine) can be used.

## Choice of HBV Vaccine for Infants, Children, and Adolescents

For infants, only the single-antigen hepatitis B vaccines (Engerix-B or Recombivax-HB) are recommended for the birth dose vaccine.[13] Pediarix, containing hepatitis B, DTaP, and inactivated polio vaccine, is approved starting at 2 months of age up through age 6 years, and this 3-dose series can be used to complete the hepatitis B vaccination after a single-antigen hepatitis B vaccine birth dose is given.[13] In general, rates of protective immunity are similar across different hepatitis B vaccines in immunocompetent infants, children, and adolescents, and vaccine brands are interchangeable within an immunization series.[13] Due to a lack of data on the interchangeability of acellular pertussis-containing vaccines, the American Academy of Pediatrics recommends vaccines from the same manufacturer be used for the pertussis series.[26]

## Vaccine Dosing in Persons Receiving Hemodialysis

For persons older than 20 years of age who are receiving hemodialysis, it is important to note that higher doses of Recombivax-HB (40 µg per dose) and Engerix-B (40 µg per dose) are needed due to poor vaccine response rates with standard doses of these vaccines in this population; in addition, when Engerix-B is used for persons on hemodialysis, the usual 3-dose vaccine schedule (0, 1, and 6 months) is expanded to four doses (0, 1, 2, and 6 months) (Figure 6).[13] Persons younger than 20 years of age should receive Recombivax-HB (5 µg per dose) or Engerix-B (10 µg per dose). Although limited data suggest Heplisav-B (a 3-dose schedule with standard dosing) and Twinrix (standard schedule and dosing) may lead to higher rates of HBV seroprotection in hemodialysis patients, there are no specific ACIP recommendations for the use of either of these vaccines in persons receiving hemodialysis.[27,28,29,30]

## HBV Immunization in Adults with HIV

For adults with HIV, the two dose Heplisav-B vaccine is preferentially recommended, given high rates of seroconversion.[22,31] If, however, a recombinant three-dose vaccine (Engerix-B or Recombivax-HB) is used, guidelines recommend administering a double dose (with each dose) for 3 total doses as the primary vaccine series; a 2-dose series with Heplisav-B is considered an alternative (Figure 7).[22] This recommendation for the use of double-dose vaccine with Engerix-B or Recombivax-HB is based on data from a meta-analysis of 10 studies showing improved response rates at 4 to 6 weeks and at 12 months post vaccine when double doses are compared to standard doses.[32] For persons with HIV who do not respond to a series with (Engerix-B or Recombivax-HB), repeat immunization is recommended, giving 2 or 3 doses of Heplisav-B.[22,33]

## Interruption in Schedule

Longer intervals between doses 1 and 2 or doses 2 and 3 of Engerix-B and Recombivax-HB vaccines have not been shown to diminish efficacy, and if anything, a longer than recommended interval between the last two doses of vaccine may confer higher levels of protection.[\[13\]](#) As such, there is no need to restart the hepatitis B vaccine series in situations where the vaccination schedule has been interrupted. Subsequent doses should be given as soon as possible, making sure the first and second doses are separated by at least 4 weeks, the second and third doses are separated by at least 8 weeks, and the third dose is at least 16 weeks after the first dose.[\[13\]](#)

## Minimum Acceptable Intervals Between Doses

For Engerix-B, Recombivax-HB, and Heplisav-B, the minimal acceptable dosing interval between the first and second dose of vaccine is 4 weeks ([Figure 8](#)).[\[7,13\]](#) The second and third doses of Engerix-B and Recombivax-HB should be given at least 8 weeks apart, and the first and third doses of vaccine should be separated by at least 16 weeks.[\[7,13\]](#) In infants, the third dose of vaccine (Engerix-B, Recombivax-HB, or Pediarix) should not be administered before 24 weeks of age.[\[13\]](#) For all hepatitis B vaccines and all intervals, doses administered up to 4 days before the minimal acceptable dosing intervals are valid; however, doses administered 5 or more days before the minimum dosing interval must be repeated using the correct schedule.[\[13\]](#) The one exception to these dosing intervals is accelerated administration of Twinrix, which can be given in adults at 0, 7, and 21 days, followed by a fourth dose at 12 months.[\[13\]](#) In the case of accelerated Twinrix, the 4-day grace period does not apply.[\[13\]](#)



## Response to HBV Vaccines

### Response to HBV Vaccines

The overall responses to all hepatitis B vaccines in healthy children and adults have been very good. Lower responses have been seen in persons undergoing hemodialysis and immunocompromised persons, including persons with HIV.

- **Engerix B and Recombivax-HB:** After three doses of the hepatitis B vaccine, more than 95% of healthy infants and more than 90% of healthy adults younger than 40 years of age achieve protective immunity, defined as an HBsAb level of 10 mIU/mL or greater.[[34,35,36](#)] Although it is optimal to administer the complete hepatitis B vaccine series, studies have shown that 32 to 56% of persons can achieve protective levels of anti-hepatitis B surface antibody (HBsAb) with a single dose of Recombivax-HB or Engerix-B, and 70 to 75% achieve protective levels with two doses of vaccine.[[34,36](#)]
- **Twinrix:** In an open-label, randomized, control trial of Twinrix versus single-antigen hepatitis A vaccine plus single-antigen hepatitis B vaccine in healthy adults 19 years of age and older, HAV seroconversion and HBV seroprotection occurred in 95.1% of subjects in the Twinrix arm versus 92.2% of subjects in the monovalent vaccine arm.[[37](#)]
- **Heplisav-B:** Responses to the two-dose Heplisav-B vaccine are excellent. In phase 3 registration trials that collectively enrolled 9,597 adults aged 18 through 70 years, the rate of seroprotection rate (SPR) after two doses of Heplisav-B, spaced one month apart, was 90 to 100%, compared with 71 to 90% for standard single-antigen hepatitis B vaccine (Engerix-B) for three doses ([Figure 9](#)) and ([Figure 10](#)).[[38, 39,40,41](#)] This improvement in seroconversion rates is particularly notable among groups that have historically had lower seroprotective responses to recombinant hepatitis B vaccines, including in persons with older age, diabetes mellitus, tobacco use, and/or obesity.[[7,38,39,42](#)]

### Reduced Response to Vaccine

Despite generally high rates of seroconversion in healthy adults, certain conditions are associated with decreased response to vaccine ([Table 5](#)).[[13,24,43,44,45](#)] A lack of response in healthy individuals has been linked to genetic determinants, specifically HLA haplotypes. In studies from the United States and Sweden, HLA haplotypes B8, SC01, DR3, DQB1\*0604, DQA1\*0102, and DRB1\*1302 were associated with lower response rates to hepatitis B vaccine.[[46,47](#)] Nevertheless, the presence of the same haplotypes among some responders in these studies suggests that genetic determinants may be only one of the factors impacting response to hepatitis B vaccine.[[46,47](#)]

### HBV Vaccine in Persons Receiving Hemodialysis

Among persons with chronic kidney disease, the serologic response rates to Engerix-B and Recombivax-HB vaccines (using standard HBsAg doses and standard dosing schedules) are only about 50 to 60%. To improve the vaccine response in adults receiving hemodialysis, each dose of HBsAg in Engerix-B is increased (from 20 µg to 40 µg), and the dosing schedule is expanded from three doses (0, 1, and 6 months) to four doses (0, 1, 2, and 6 months). Similarly, when giving Recombivax-HB to adults receiving hemodialysis, each HBsAg dose is increased from 10 µg to 40 µg, but the same schedule is used (0, 1, and 6 months). In an observer-blind, randomized trial in adults receiving hemodialysis, investigators compared a 3-dose Heplisav-B series (0, 1, and 6 months) with the 4-dose series (0, 1, 2, and 6 months) of double-dose (40 µg) Engerix-B in persons receiving hemodialysis; the seroprotective response rates at weeks 28 and 52 were higher with Heplisav-B than with Engerix-B.[[27](#)] Although this study showed promise with a 3-dose Heplisav-B series in persons on hemodialysis, at this time there are insufficient data on the use of Heplisav-B in persons on hemodialysis.

### Duration of Immunity

In general, protection generated by a complete vaccine series is believed to last for at least 30 years in most healthy individuals, and immunity in healthy adults and children appears to persist even though antibodies may decline over time, even below the limit of detection.[[48](#),[49](#),[50](#),[51](#),[52](#)] This is evidenced by a study of seroprotection rates in 423 adolescents who received HBV vaccination as infants. In this study, only 24% of participants had protective HBsAb levels of 10 mIU/mL or greater at baseline, but 92% achieved protective levels after a challenge dose of vaccine.[[53](#)] A similar study of 243 Alaska Native persons who were vaccinated in infancy showed that 51% had HBsAb levels of 10 mIU/mL or greater after 30 years, and among those with HBsAb levels less than 10 mIU/mL, 88% responded to a booster dose of hepatitis B vaccine, achieving HBsAb levels of 10 mIU/mL or greater.[[54](#)] In a subsequent study done within the same Alaska Native population, a group of 112 persons who responded to the initial hepatitis B vaccine series were evaluated 35 years later, and 47% had HBsAb levels of 10 mIU/mL or greater; among those with HBsAb levels less than 10 mIU/mL, 74% responded to a booster dose of hepatitis B vaccine, achieving HBsAb levels of 10 mIU/mL or greater.[[52](#)] Based on the proportion of individuals who had anti-HBs levels of 10 mIU/mL or greater at 35 years after immunization and following one booster dose, the authors concluded that 86% of individuals had serologic evidence of HBV protection 35 years following initial vaccination.[[52](#)]

## Postvaccination Serologic Testing

### Indications for Postvaccination Serologic Testing

Postvaccination testing for levels of HBsAb is not recommended following routine hepatitis B immunization of infants, children, adolescents, or adults.[13] The rationale for this recommendation is that most healthy persons have an excellent response to the hepatitis B vaccine series. Postvaccination serologic testing should be considered for persons who have known ongoing risk for hepatitis B exposure, known diminished protective response to vaccine, or whose clinical management depends on knowledge of their HBV immune status. The purpose of testing in these situations is to determine the need for revaccination, and in the case of sex partners, the need for additional protective measures.[13] The CDC recommends hepatitis B postvaccination serologic testing to determine vaccine immune response in the following groups:[13]

- Infants born to HBsAg-positive mothers
- Infants born to mothers whose HBsAg status remains unknown
- Health care workers and public safety workers at risk of continued exposure to blood and body fluids
- Hemodialysis patients and others who might require outpatient hemodialysis (e.g., predialysis, peritoneal dialysis, and home dialysis)
- Persons with HIV and other immunocompromised persons (e.g., hematopoietic stem-cell transplant recipients or persons receiving chemotherapy)
- Sex partners of HBsAg-positive persons

### Timing and Method of Postvaccination Serologic Testing

For persons who have an indication for postvaccination serologic testing, the testing should be performed 1 to 2 months after completion of the hepatitis B vaccine series, regardless of which hepatitis B vaccine was used.[7,13] The goal of postvaccination serologic testing is to assess immunity against HBV; performing a quantitative anti-HBs is the recommended test for this assessment. Of note, serologic testing for infants born to HBsAg-positive mothers (or HBsAg-unknown mothers) should also include testing for HBsAg. These infants should have testing performed 1 to 2 months after completing the hepatitis B vaccine series; if the infant received the hepatitis B vaccine on a normal schedule then serologic testing would occur at about 9 to 12 months of age. Deferring the anti-HBs testing until after 9 months of age is important, since these infants may have residual anti-HBs out to 9 months from the hepatitis B immune globulin received at birth.[11,13,55] Testing of anti-HBc in infants should be avoided, since maternal anti-HBc may persist for at least 24 months.[11] For all ages, following any dose of hepatitis B vaccine, if HBsAg testing is needed to evaluate for active infection, the HBsAg test should be deferred for at least 1 month after receipt of a hepatitis B vaccine dose since the recombinant HBsAg in the hepatitis B vaccines can cause a transient false-positive HBsAg test for up to 18 days after vaccination.[55,56,57,58]

### Interpretation of Postvaccination Serologic Testing

Anti-HBs levels of 10 mIU/mL or greater have been shown to strongly correlate with protection against HBV infection, although that exact threshold may vary from assay to assay.[59,60] As such, those with anti-HBs levels of at least 10 mIU/mL following hepatitis B immunization are considered immune to HBV and protected against infection with HBV.[11,12,13,60] For assays that utilize a cutoff different than 10 mIU/mL, it is important to refer to the package insert of the test used to appropriately interpret the results and determine the correct level of anti-HBs antibodies.[59,60]

### Repeat Postvaccination Serologic Testing

Given the higher incidence of HBV infection among patients on long-term dialysis, patients undergoing outpatient hemodialysis should have anti-HBs testing yearly.[13,61] If anti-HBs levels fall below 10 mIU/mL, a booster dose of hepatitis B vaccine should be administered. In this setting, serologic testing to assess

response is not recommended at 1-2 months.[13] The need for repeat postvaccination serologic testing has not been established in other high-risk populations, such as persons with HIV, hematopoietic stem-cell transplant recipients, and those receiving chemotherapy or other immunosuppressive drugs.[13] In these populations, the ACIP recommends consideration of annual anti-HBs testing with booster dose vaccination for persons at ongoing risk for HBV acquisition.[13]

## **Testing Health Care Workers Vaccinated in the Past**

The ACIP suggests health care institutions consider assessing preexposure immunity to HBV in all health care workers at the time of hire, regardless of vaccination status.[13] For health care workers with prior documentation of hepatitis B vaccine, testing for anti-HBs levels should be performed. If anti-HBs levels are 10 mIU/mL or greater, the health care worker is considered immune, and no HBV postexposure prophylaxis is needed following a potential exposure.[13] Health care workers with previous immunization against HBV and anti-HBs levels less than 10 mIU/mL should receive a one-time dose of hepatitis B vaccine, followed by postvaccination serologic testing 1-2 months later.[13] If the anti-HBs level remains less than 10 mIU/mL, administration of 2 additional doses of hepatitis B vaccine is recommended, again followed by postvaccination serologic testing. If, after repeat hepatitis B vaccination, the health care worker fails to mount a protective immune response (defined as anti-HBs levels 10 mIU/mL or greater), they should be counseled on the need for postexposure prophylaxis following exposure.[13] If a health care institution decides against measuring anti-HBs levels in their health care workers, they should ensure the health care workers seek timely evaluation for postexposure prophylaxis and assessment after any potential occupational exposure to HBV.[13]

## Management of HBV Vaccine Nonresponders

### Recommended Approach to HBV Vaccine Nonresponders in the General Population

Approximately 5 to 10% of immunized individuals fail to develop a protective antibody response (HBsAb level less than 10 mIU/mL) after a complete initial hepatitis B vaccine series. For persons who fail to generate adequate antibody levels in response to a primary hepatitis B vaccine series, revaccination can achieve a protective response at least half of the time.[13,62,63,64] The following summarizes CDC recommended options for revaccination of hepatitis B vaccine nonresponders (in the general population).

- Administer a single hepatitis B vaccine dose followed by anti-HBs testing 1-2 months later, with completion of the second full series if repeat anti-HBs remains less than 10 mIU/mL, *or*
- Repeat vaccination with a second full 3-dose hepatitis B vaccine series, *or*
- Repeat vaccination with a 2-dose series of Heplisav-B.

Nonresponders to a second vaccine series are unlikely to develop a protective response to further doses of vaccine.[65]

### Recommended Approach to HBV Vaccine Nonresponders in Key Populations

The following represents recommendations for the approach to persons who do not respond to the initial hepatitis B vaccine series. Most of these recommendations are based on guidance from the CDC and ACIP, and focus on groups for which postvaccination serologic testing is recommended.[13]

- **Infants Born to HBsAg-Positive Mothers:** In most circumstances, the approach to HBsAg-negative infants who were born to an HBsAg-positive mother requires a stepwise approach (Figure 11).[13] If infant serologic testing at 9-12 months of age shows the infant did not respond to the initial hepatitis B vaccine series (anti-HBs level less than 10 mIU/mL), they should receive 1 additional dose of hepatitis B vaccine, followed by repeat serologic testing 1-2 months later.[13] If, at that point, the infant's anti-HBs level remains less than 10 mIU/mL, they should receive two additional doses of hepatitis B vaccine to complete a second 3-dose series.[13] Serologic testing (anti-HBs) should be performed 1-2 months after completion of the second hepatitis B vaccine series.[13] Alternatively, based on family preference and clinical circumstances, it is reasonable to give a full repeat 3-dose vaccine series to infants who did not respond to the initial vaccine series.[13]
- **Health Care Workers:** All health care workers who receive hepatitis B vaccination should have postvaccination serologic testing; vaccine nonresponders need further management (Figure 12).[13] Previously vaccinated health care personnel with an anti-HBs level less than 10 mIU/mL should receive one additional dose of hepatitis B vaccine followed by repeat serologic testing in 1 to 2 months.[13] If anti-HBs remains less than 10 mIU/mL following a booster dose, two additional doses of vaccine should be administered, followed by repeat anti-HBs serologic screening 1-2 months after the final dose of vaccine.[13] As with infants, health care workers with anti-HBs less than 10 mIU/mL may find it more practical to receive a second complete hepatitis B vaccine series followed by repeat serologic testing at 1-2 months, as opposed to the stepwise strategy outlined above that begins with giving one dose.[13] In addition, the two-dose series of Heplisav-B should be considered in health care workers who require revaccination.[13] In a study of health care workers who did not respond to at least 5 doses of hepatitis B vaccine (Engerix-B or Recombivax), 91% (43 of 47) developed seroprotective responses after 2 doses of Heplisav-B.[66]
- **Immunocompromised Adults:** Hematopoietic stem-cell transplant recipients, persons with HIV, and persons receiving immunosuppressant medications who are HBsAg-negative and do not respond to initial hepatitis B vaccination (anti-HBs less than 10 mIU/mL 1-2 months after completing the initial series) should receive a second complete hepatitis B vaccine series, making certain all doses are given on schedule (Figure 13).[13] For persons with HIV who failed prior Engerix-B or Recombivax-HB,

guidelines recommend revaccination using the two dose Heplisav-B vaccine, with consideration for a third dose of Heplisav-B at 24 weeks.[22,33] There are limited data for persons with HIV who fail to respond to a two-dose Heplisav-B series, but in such instances, a third dose of Heplisav-B 24 weeks after the first dose should be considered.[22] For all immunocompromised persons, anti-HBs testing should be performed again, ideally 1-2 months after completing the second vaccine series.[13] If the anti-HBs concentration remains less than 10 mIU/mL, then HBsAg testing should be performed to determine whether active HBV infection is the cause of vaccine nonresponse.[13] If the HBsAg test is negative, the person should be considered at risk for acquiring HBV infection, and they should receive counseling regarding prevention of HBV infection; persons who test positive for HBsAg should be considered to have HBV infection and should receive further evaluation, management, and counseling.[13] Administering more than two complete hepatitis B vaccine series is generally not recommended for this population.

- **Hemodialysis Patients:** Hemodialysis patients who do not respond to the hepatitis B vaccine should be managed similar to other immunocompromised adults, with the exception that hemodialysis patients who respond to the second vaccine series should undergo yearly anti-HBs screening (Figure 14).[12,28] If anti-HBs levels fall below 10 mIU/mL, a booster dose of hepatitis B vaccine should be administered.[13] In this setting, given the frequency of anti-HBs screening, serologic testing to assess response to additional doses of vaccine is not recommended at 1-2 months after the booster dose.[12,13]

## Additional Strategies for the Management of HBV Vaccine Nonresponders

Several additional strategies have been utilized in managing persons who do not respond to the initial hepatitis B vaccine series, but none of these have been established to have better efficacy in the general population than the strategy outlined in the CDC recommendations for hepatitis B vaccine nonresponders.[67] The following summarizes strategies that have been employed in the management of hepatitis B vaccine nonresponders.

- **Increased Vaccine Doses or Antigen per Dose:** There are several studies that have evaluated the efficacy of using increased hepatitis B vaccine doses for the management of nonresponders. One study of 48 healthy adult nonresponders showed that revaccination with a double dose of combined hepatitis A and B vaccine (Twinrix) led to protective titers (anti-HBs levels 10 mIU/mL or greater) in 95% of study subjects.[68] A similar study evaluated double-dose versus single-dose hepatitis B vaccine in health care workers who did not previously respond to hepatitis B vaccination. In this study, 97.8% of those receiving the double dose and 89.6% of those receiving the single dose developed anti-HBs titers of 10 mIU/mL or greater; this difference, however, was not statistically significant.[69] Moreover, a systematic review and meta-analysis of vaccine options for adults who did not respond to prior hepatitis B vaccination showed no statistical difference in rates of protective anti-HBs levels between those who were revaccinated with standard dose hepatitis B vaccine versus those who received a double dose of hepatitis B vaccine.[67]
- **Intradermal Administration:** There is some data supporting the enhanced immunogenicity of intradermal versus intramuscular hepatitis B vaccination. In one study of 50 previously vaccinated hemodialysis patients without protective anti-HBs levels, revaccination with intradermal hepatitis B vaccine, in comparison to intramuscular hepatitis B vaccine, yielded statistically higher rates of seroprotection at 1, 12, and 20 months.[70] A similar study of hepatitis B vaccine nonresponders on hemodialysis showed significantly higher seroconversion rates (79% vs 40%) among hemodialysis patients who received weekly intradermal vaccine for 8 weeks versus those who received intramuscular vaccine at 1 and 8 weeks.[71] In addition to patients on hemodialysis, intradermal vaccination has been shown to be effective in patients with chronic liver disease. In one study of 42 patients with chronic liver disease who failed initial intramuscular hepatitis B vaccination, 69% had an immunologic response (anti-HBs 10 mIU/mL or greater) after repeat vaccination with up to three doses of intradermal vaccine.[72] It should be noted, however, that intradermal vaccines are challenging to administer, and injection into the subcutaneous tissue yields lower rates of protection. Because of this, their widespread use is limited by the availability of skilled personnel to administer the vaccine.



## Summary Points

- In the United States, overall hepatitis B vaccine delivery and coverage rates among adults is low, despite high rates of vaccine acceptance among adults who are offered the vaccine.
- All infants, children, adolescents younger than 19 years of age, adults 19 to 59 years, and adults 60 years of age and older with risk factors for HBV should receive hepatitis B vaccination. Adults 60 years of age and older without risk factors for HBV may receive the hepatitis B vaccine.
- In general, prevaccination serologic testing is not indicated unless the person is at high risk for HBV infection.
- There are three single-antigen hepatitis B vaccines and one hepatitis A-hepatitis B combination vaccine approved for adults in the United States. The ACIP does not provide preferential guidance on which vaccine to use, and all can be used in pregnant women.
- In infants, only single-antigen HBV vaccines (Engerix-B or Recombivax-HB) should be used for the birth dose hepatitis B vaccine, but combination vaccines can be used to complete the hepatitis B vaccine series.
- Overall response to hepatitis B vaccination is good, with greater than 90% of healthy adults achieving protective immunity after three doses of vaccine, defined as an HBsAb level of 10 mIU/mL or greater.
- Age greater than 40 years, male sex, obesity, diabetes, tobacco smoking, chronic hepatitis C infection, alcohol use disorder, renal disease, HIV infection, celiac disease, other immune compromising conditions, and certain genetic determinants have been associated with suboptimal response to hepatitis B vaccination.
- Postvaccination serologic testing is indicated for the following groups: infants born to HBsAg-positive mothers or mothers of unknown HBsAg status, health care workers and public safety workers at risk for exposure to blood or body fluids, persons on hemodialysis, persons with HIV, other immunocompromised persons, and sex partners of HBsAg-positive persons.
- For the estimated 5 to 10% of individuals who fail to develop a protective antibody response to an initial 3-dose hepatitis B vaccine series, a fourth vaccine dose or a second full 3-dose revaccination series can achieve a protective response in at least 50% of these persons.
- Novel adjuvants, double-dose vaccinations, intradermal vaccines, and vaccines containing proteins in the pre-S1 and pre-S2 regions on the HBV envelope have been used to elicit better immune responses in vaccine nonresponders.



## Citations

1. World Health Organization. Global Hepatitis Report 2024. Geneva: World Health Organization; April 9, 2024:1-244.  
[\[WHO\]](#) -
2. Weng MK, Doshani M, Khan MA, et al. Universal Hepatitis B Vaccination in Adults Aged 19-59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:477-83.  
[\[PubMed Abstract\]](#) -
3. Zanetti AR, Van Damme P, Shouval D. The global impact of vaccination against hepatitis B: a historical overview. Vaccine. 2008;26:6266-73.  
[\[PubMed Abstract\]](#) -
4. Stephenne J. Development and production aspects of a recombinant yeast-derived hepatitis B vaccine. Vaccine. 1990;8 Suppl:S69-73; discussion S79-80.  
[\[PubMed Abstract\]](#) -
5. Szmunes W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med. 1980;303:833-41.  
[\[PubMed Abstract\]](#) -
6. Young MD, Schneider DL, Zuckerman AJ, Du W, Dickson B, Maddrey WC. Adult hepatitis B vaccination using a novel triple antigen recombinant vaccine. Hepatology. 2001;34:372-6.  
[\[PubMed Abstract\]](#) -
7. Schillie S, Harris A, Link-Gelles R, Romero J, Ward J, Nelson N. Recommendations of the Advisory Committee on Immunization Practices for Use of a Hepatitis B Vaccine with a Novel Adjuvant. MMWR Morb Mortal Wkly Rep. 2018;67:455-8.  
[\[PubMed Abstract\]](#) -
8. Lu PJ, Hung MC, Srivastav A, et al. Surveillance of Vaccination Coverage Among Adult Populations -United States, 2018. MMWR Surveill Summ. 2021;70:1-26.  
[\[PubMed Abstract\]](#) -
9. Weinbaum CM, Lyerla R, Mackellar DA, et al. The Young Men's Survey phase II: hepatitis B immunization and infection among young men who have sex with men. Am J Public Health. 2008;98:839-45.  
[\[PubMed Abstract\]](#) -
10. Centers for Disease Control and Prevention (CDC).. Use of hepatitis B vaccination for adults with diabetes mellitus: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortal Wkly Rep. 2011;60:1709-11.  
[\[PubMed Abstract\]](#) -
11. Mast EE, Margolis HS, Fiore AE, et al. A comprehensive immunization strategy to eliminate transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) part 1: immunization of infants, children, and adolescents. MMWR Recomm Rep. 2005;54:1-31.  
[\[PubMed Abstract\]](#) -
12. Mast EE, Weinbaum CM, Fiore AE, et al. A comprehensive immunization strategy to eliminate

transmission of hepatitis B virus infection in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP) Part II: immunization of adults. MMWR Recomm Rep. 2006;55:1-33.

[\[PubMed Abstract\]](#) -

13. Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018;67:1-31.

[\[PubMed Abstract\]](#) -

14. Centers for Disease Control (CDC). Recommendation of the Immunization Practices Advisory Committee (ACIP). Inactivated hepatitis B virus vaccine. MMWR Morb Mortal Wkly Rep. 1982;31:317-22, 327-8.

[\[PubMed Abstract\]](#) -

15. Iqbal K, Kleven RM, Kainer MA, et al. Epidemiology of Acute Hepatitis B in the United States From Population-Based Surveillance, 2006-2011. Clin Infect Dis. 2015;61:584-92.

[\[PubMed Abstract\]](#) -

16. Bradley H, Hall E, Asher A, et al. Estimated number of people who inject drugs in the United States. Clin Infect Dis. 2022 Jul 6. Online ahead of print.

[\[PubMed Abstract\]](#) -

17. Centers for Disease Control and Prevention (CDC). 2022 Viral Hepatitis Surveillance Report—Hepatitis B. Published April 2024.

[\[CDC\]](#) -

18. Blostein J, Clark PA. Cost-effectiveness of preimmunization hepatitis B screening in high-risk adolescents. Public Health Rep. 2001;116:165-8.

[\[PubMed Abstract\]](#) -

19. Centers for Disease Control and Prevention. Hepatitis B vaccination of inmates in correctional facilities--Texas, 2000-2002. MMWR Morb Mortal Wkly Rep. 2004;53:681-3.

[\[PubMed Abstract\]](#) -

20. Hu Y, Grau LE, Scott G, et al. Economic evaluation of delivering hepatitis B vaccine to injection drug users. Am J Prev Med. 2008;35:25-32.

[\[PubMed Abstract\]](#) -

21. Weinbaum CM, Williams I, Mast EE, et al. Recommendations for identification and public health management of persons with chronic hepatitis B virus infection. MMWR Recomm Rep. 2008;57:1-20.

[\[PubMed Abstract\]](#) -

22. Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Hepatitis B virus infection. Last Updated: December 16, 2024.

[\[HIV.gov\]](#) -

23. Weber DJ, Rutala WA, Samsa GP, Santimaw JE, Lemon SM. Obesity as a predictor of poor antibody response to hepatitis B plasma vaccine. JAMA. 1985;254:3187-9.

[\[PubMed Abstract\]](#) -

24. Shaw FE Jr, Guess HA, Roets JM, et al. Effect of anatomic injection site, age and smoking on the immune response to hepatitis B vaccination. *Vaccine*. 1989;7:425-30.  
[\[PubMed Abstract\]](#) -
25. Sandul AL, Rapposelli K, Nyendak M, Kim M. Updated Recommendation for Universal Hepatitis B Vaccination in Adults Aged 19-59 Years - United States, 2024. *MMWR Morb Mortal Wkly Rep*. 2024;73:1106.  
[\[PubMed Abstract\]](#) -
26. Liang JL, Tiwari T, Moro P, et al. Prevention of Pertussis, Tetanus, and Diphtheria with Vaccines in the United States: Recommendations of the Advisory Committee on Immunization Practices (ACIP). *MMWR Recomm Rep*. 2018;67:1-44.  
[\[PubMed Abstract\]](#) -
27. Janssen RS, Mangoo-Karim R, Pergola PE, et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease. *Vaccine*. 2013;31:5306-13.  
[\[PubMed Abstract\]](#) -
28. Centers for Disease Control and Prevention. Guidelines for Vaccinating Kidney Dialysis Patients and Patients with Chronic Kidney Disease. December 2012.  
[\[CDC\]](#) -
29. Tung J, Carlisle E, Smieja M, Kim PT, Lee CH. A randomized clinical trial of immunization with combined hepatitis A and B versus hepatitis B alone for hepatitis B seroprotection in hemodialysis patients. *Am J Kidney Dis*. 2010;56:713-9.  
[\[PubMed Abstract\]](#) -
30. Awad AM, Ntoso A, Connaire JJ, et al. An open-label, single-arm study evaluating the immunogenicity and safety of the hepatitis B vaccine HepB-CpG (HEPLISAV-B®) in adults receiving hemodialysis. *Vaccine*. 2021;39:3346-52.  
[\[PubMed Abstract\]](#) -
31. Marks KM, Kang M, Umbleja T, et al. Immunogenicity and Safety of Hepatitis B Virus (HBV) Vaccine With a Toll-Like Receptor 9 Agonist Adjuvant in HBV Vaccine-Naïve People With Human Immunodeficiency Virus. *Clin Infect Dis*. 2023;77:414-8.  
[\[PubMed Abstract\]](#) -
32. Lee JH, Hong S, Im JH, Lee JS, Baek JH, Kwon HY. Systematic review and meta-analysis of immune response of double dose of hepatitis B vaccination in HIV-infected patients. *Vaccine*. 2020;38:3995-4000.  
[\[PubMed Abstract\]](#) -
33. Marks KM, Kang M, Umbleja T, et al. HepB-CpG vs HepB-Alum Vaccine in People With HIV and Prior Vaccine Nonresponse: The BEE-HIVE Randomized Clinical Trial. *JAMA*. 2024 Dec 1. Online ahead of print.  
[\[PubMed Abstract\]](#) -
34. Zajac BA, West DJ, McAleer WJ, Scolnick EM. Overview of clinical studies with hepatitis B vaccine made by recombinant DNA. *J Infect*. 1986;13 Suppl A:39-45.  
[\[PubMed Abstract\]](#) -
35. Averhoff F, Mahoney F, Coleman P, Schatz G, Hurwitz E, Margolis H. Immunogenicity of hepatitis B Vaccines. Implications for persons at occupational risk of hepatitis B virus infection. *Am J Prev Med*.

1998;15:1-8.

[\[PubMed Abstract\]](#) -

36. André FE. Summary of safety and efficacy data on a yeast-derived hepatitis B vaccine. *Am J Med.* 1989;87:14S-20S.  
[\[PubMed Abstract\]](#) -
37. Joines RW, Blatter M, Abraham B, et al. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults. *Vaccine.* 2001;19:4710-9.  
[\[PubMed Abstract\]](#) -
38. Jackson S, Lentino J, Kopp J, et al. Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults. *Vaccine.* 2018;36:668-674.  
[\[PubMed Abstract\]](#) -
39. Heyward WL, Kyle M, Blumenau J, et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age. *Vaccine.* 2013;31:5300-5.  
[\[PubMed Abstract\]](#) -
40. Halperin SA, Ward B, Cooper C, et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. *Vaccine.* 2012;30:2556-63.  
[\[PubMed Abstract\]](#) -
41. Halperin SA, Dobson S, McNeil S, et al. Comparison of the safety and immunogenicity of hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligonucleotide and a licensed hepatitis B vaccine in healthy young adults. *Vaccine.* 2006;24:20-6.  
[\[PubMed Abstract\]](#) -
42. Sablan BP, Kim DJ, Barzaga NG, et al. Demonstration of safety and enhanced seroprotection against hepatitis B with investigational HBsAg-1018 ISS vaccine compared to a licensed hepatitis B vaccine. *Vaccine.* 2012;30:2689-96.  
[\[PubMed Abstract\]](#) -
43. Bruguera M, Cremades M, Salinas R, Costa J, Grau M, Sans J. Impaired response to recombinant hepatitis B vaccine in HIV-infected persons. *J Clin Gastroenterol.* 1992;14:27-30.  
[\[PubMed Abstract\]](#) -
44. Lacson E, Teng M, Ong J, Vienneau L, Ofsthun N, Lazarus JM. Antibody response to Engerix-B and Recombivax-HB hepatitis B vaccination in end-stage renal disease. *Hemodial Int.* 2005;9:367-75.  
[\[PubMed Abstract\]](#) -
45. Mendenhall C, Roselle GA, Lybecker LA, et al. Hepatitis B vaccination. Response of alcoholic with and without liver injury. *Dig Dis Sci.* 1988;33:263-9.  
[\[PubMed Abstract\]](#) -
46. Alper CA, Kruskall MS, Marcus-Bagley D, et al. Genetic prediction of nonresponse to hepatitis B vaccine. *N Engl J Med.* 1989;321:708-12.  
[\[PubMed Abstract\]](#) -

47. Langö-Warensjö A, Cardell K, Lindblom B. Haplotypes comprising subtypes of the DQB1\*06 allele direct the antibody response after immunisation with hepatitis B surface antigen. *Tissue Antigens*. 1998;52:374-80.  
[\[PubMed Abstract\]](#) -
48. Zanetti AR, Mariano A, Romanò L, et al. Long-term immunogenicity of hepatitis B vaccination and policy for booster: an Italian multicentre study. *Lancet*. 2005;366:1379-84.  
[\[PubMed Abstract\]](#) -
49. Fitzsimons D, François G, Hall A, et al. Long-term efficacy of hepatitis B vaccine, booster policy, and impact of hepatitis B virus mutants. *Vaccine*. 2005;23:4158-66.  
[\[PubMed Abstract\]](#) -
50. Bauer T, Jilg W. Hepatitis B surface antigen-specific T and B cell memory in individuals who had lost protective antibodies after hepatitis B vaccination. *Vaccine*. 2006;24:572-7.  
[\[PubMed Abstract\]](#) -
51. Gara N, Abdalla A, Rivera E, et al. Durability of antibody response against hepatitis B virus in healthcare workers vaccinated as adults. *Clin Infect Dis*. 2015;60:505-13.  
[\[PubMed Abstract\]](#) -
52. Bruce MG, Bruden D, Hurlburt D, et al. Protection and antibody levels 35 years after primary series with hepatitis B vaccine and response to a booster dose. *Hepatology*. 2022 Mar 23. Online ahead of print.  
[\[PubMed Abstract\]](#) -
53. Middleman AB, Baker CJ, Kozinetz CA, et al. Duration of protection after infant hepatitis B vaccination series. *Pediatrics*. 2014;133:e1500-7.  
[\[PubMed Abstract\]](#) -
54. Bruce MG, Bruden D, Hurlburt D, et al. Antibody Levels and Protection After Hepatitis B Vaccine: Results of a 30-Year Follow-up Study and Response to a Booster Dose. *J Infect Dis*. 2016;214:16-22.  
[\[PubMed Abstract\]](#) -
55. Schillie S, Murphy TV, Fenlon N, Ko S, Ward JW. Update: Shortened Interval for Postvaccination Serologic Testing of Infants Born to Hepatitis B-Infected Mothers. *MMWR Morb Mortal Wkly Rep*. 2015;64:1118-20.  
[\[PubMed Abstract\]](#) -
56. Challapalli M, Naidu V, Cunningham DG. Hepatitis B surface antigenemia in a newborn infant after vaccination. *Pediatr Infect Dis J*. 1993;12:408-9.  
[\[PubMed Abstract\]](#) -
57. Fleischer L, Syed SS. Hepatitis B surface antigenemia in a neonate following vaccination with Pediarix. *Clin Pediatr (Phila)*. 2009;48:311-2.  
[\[PubMed Abstract\]](#) -
58. Onuigbo MA, Nesbit A, Weisenbeck J, Hurlburt J. Hepatitis B surface antigenemia following recombinant Engerix B hepatitis B vaccine in an 81-year-old ESRD patient on hemodialysis. *Ren Fail*. 2010;32:531-2.  
[\[PubMed Abstract\]](#) -
59. Hadler SC, Francis DP, Maynard JE, et al. Long-term immunogenicity and efficacy of hepatitis B vaccine in homosexual men. *N Engl J Med*. 1986;315:209-14.

[\[PubMed Abstract\]](#) -

60. Jack AD, Hall AJ, Maine N, Mendy M, Whittle HC. What level of hepatitis B antibody is protective? *J Infect Dis.* 1999;179:489-92.  
[\[PubMed Abstract\]](#) -
61. Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. *Semin Dial.* 2005;18:52-61.  
[\[PubMed Abstract\]](#) -
62. Goldwater PN. Randomized, comparative trial of 20 micrograms vs 40 micrograms Engerix B vaccine in hepatitis B vaccine non-responders. *Vaccine.* 1997;15:353-6.  
[\[PubMed Abstract\]](#) -
63. Bertino JS Jr, Tirrell P, Greenberg RN, et al. A comparative trial of standard or high-dose S subunit recombinant hepatitis B vaccine versus a vaccine containing S subunit, pre-S1, and pre-S2 particles for revaccination of healthy adult nonresponders. *J Infect Dis.* 1997;175:678-81.  
[\[PubMed Abstract\]](#) -
64. Halperin SA, Ward BJ, Dionne M, et al. Immunogenicity of an investigational hepatitis B vaccine (hepatitis B surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide) in nonresponders to licensed hepatitis B vaccine. *Hum Vaccin Immunother.* 2013;9:1438-44.  
[\[PubMed Abstract\]](#) -
65. Yu AS, Cheung RC, Keeffe EB. Hepatitis B vaccines. *Clin Liver Dis.* 2004;8:283-300.  
[\[PubMed Abstract\]](#) -
66. Russ RK, Vandehei HM, Golovkina MI, Mogallapalli H, Caldera F, Hayney MS. Hepatitis B-CpG Vaccine Series for Healthcare Workers Who Are Hepatitis B Vaccine Nonresponders. *Clin Infect Dis.* 2024;79:562-3.  
[\[PubMed Abstract\]](#) -
67. David MC, Ha SH, Paynter S, Lau C. A systematic review and meta-analysis of management options for adults who respond poorly to hepatitis B vaccination. *Vaccine.* 2015;33:6564-9.  
[\[PubMed Abstract\]](#) -
68. Cardell K, Akerlind B, Sällberg M, Frydén A. Excellent response rate to a double dose of the combined hepatitis A and B vaccine in previous nonresponders to hepatitis B vaccine. *J Infect Dis.* 2008;198:299-304.  
[\[PubMed Abstract\]](#) -
69. Joukar F, Mansour-Ghanaei F, Naghipour MR, Asgharnezhad M. Immune Responses to Single-Dose Versus Double-Dose Hepatitis B Vaccines in Healthcare Workers not Responding to the Primary Vaccine Series: A Randomized Clinical Trial. *Hepat Mon.* 2016;16:e32799.  
[\[PubMed Abstract\]](#) -
70. Fabrizi F, Andrulli S, Bacchini G, Corti M, Locatelli F. Intradermal versus intramuscular hepatitis b re-vaccination in non-responsive chronic dialysis patients: a prospective randomized study with cost-effectiveness evaluation. *Nephrol Dial Transplant.* 1997;12:1204-11.  
[\[PubMed Abstract\]](#) -
71. Barraclough KA, Wiggins KJ, Hawley CM, et al. Intradermal versus intramuscular hepatitis B vaccination in hemodialysis patients: a prospective open-label randomized controlled trial in

nonresponders to primary vaccination. *Am J Kidney Dis.* 2009;54:95-103.

[\[PubMed Abstract\]](#) -

72. Dhillon S, Moore C, Li SD, et al. Efficacy of high-dose intra-dermal hepatitis B virus vaccine in previous vaccination non-responders with chronic liver disease. *Dig Dis Sci.* 2012;57:215-20.

[\[PubMed Abstract\]](#) -

## References

- A Two-Dose Hepatitis B Vaccine for Adults (Heplisav-B). *JAMA.* 2018;319:822-3.  
[\[PubMed Abstract\]](#) -
- Barry M, Cooper C. Review of hepatitis B surface antigen-1018 ISS adjuvant-containing vaccine safety and efficacy. *Expert Opin Biol Ther.* 2007;7:1731-7.  
[\[PubMed Abstract\]](#) -
- Bruce MG, Bruden D, Hurlburt D, et al. Protection and antibody levels 35 years after primary series with hepatitis B vaccine and response to a booster dose. *Hepatology.* 2022;76:1180-9.  
[\[PubMed Abstract\]](#) -
- Clemens R, Sanger R, Kruppenbacher J, et al. Booster immunization of low- and non-responders after a standard three dose hepatitis B vaccine schedule--results of a post-marketing surveillance. *Vaccine.* 1997;15:349-52.  
[\[PubMed Abstract\]](#) -
- Connors EE, Panagiotakopoulos L, Hofmeister MG, et al. Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations - United States, 2023. *MMWR Recomm Rep.* 2023;72:1-25.  
[\[PubMed Abstract\]](#) -
- Fonseca MO, Pang LW, de Paula Cavalheiro N, Barone AA, Heloisa Lopes M. Randomized trial of recombinant hepatitis B vaccine in HIV-infected adult patients comparing a standard dose to a double dose. *Vaccine.* 2005;23:2902-8.  
[\[PubMed Abstract\]](#) -
- Hill HA, Elam-Evans LD, Yankey D, Singleton JA, Kang Y. Vaccination Coverage Among Children Aged 19-35 Months - United States, 2017. *MMWR Morb Mortal Wkly Rep.* 2018;67:1123-8.  
[\[PubMed Abstract\]](#) -
- Hyer R, McGuire DK, Xing B, Jackson S, Janssen R. Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults. *Vaccine.* 2018;36:2604-2611.  
[\[PubMed Abstract\]](#) -
- Janssen JM, Heyward WL, Martin JT, Janssen RS. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared with a licensed hepatitis B vaccine in patients with chronic kidney disease and type 2 diabetes mellitus. *Vaccine.* 2015;33:833-7.  
[\[PubMed Abstract\]](#) -
- Kim HN, Harrington RD, Crane HM, Dhanireddy S, Dellit TH, Spach DH. Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations. *Int J STD AIDS.* 2009;20:595-600.  
[\[PubMed Abstract\]](#) -



- Ko SC, Schillie SF, Walker T, et al. Hepatitis B vaccine response among infants born to hepatitis B surface antigen-positive women. *Vaccine*. 2014;32:2127-33.  
[[PubMed Abstract](#)] -
- Launay O, van der Vliet D, Rosenberg AR, et al. Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: a randomized controlled trial. *JAMA*. 2011;305:1432-40.  
[[PubMed Abstract](#)] -
- Lu PJ, O'Halloran A, Kennedy ED, et al. Awareness among adults of vaccine-preventable diseases and recommended vaccinations, United States, 2015. *Vaccine*. 2017;35:3104-3115.  
[[PubMed Abstract](#)] -
- Nelson NP, Easterbrook PJ, McMahon BJ. Epidemiology of Hepatitis B Virus Infection and Impact of Vaccination on Disease. *Clin Liver Dis*. 2016;20:607-28.  
[[PubMed Abstract](#)] -
- Noh KW, Poland GA, Murray JA. Hepatitis B vaccine nonresponse and celiac disease. *Am J Gastroenterol*. 2003;98:2289-92.  
[[PubMed Abstract](#)] -
- Park SD, Markowitz J, Pettei M, et al. Failure to respond to hepatitis B vaccine in children with celiac disease. *J Pediatr Gastroenterol Nutr*. 2007;44:431-5.  
[[PubMed Abstract](#)] -
- Poland GA, Jacobson RM. Clinical practice: prevention of hepatitis B with the hepatitis B vaccine. *N Engl J Med*. 2004;351:2832-8.  
[[PubMed Abstract](#)] -
- Propst T, Propst A, Lhotta K, Vogel W, König P. Reinforced intradermal hepatitis B vaccination in hemodialysis patients is superior in antibody response to intramuscular or subcutaneous vaccination. *Am J Kidney Dis*. 1998;32:1041-5.  
[[PubMed Abstract](#)] -
- Rey D, Krantz V, Partisani M, et al. Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load. *Vaccine*. 2000;18:1161-5.  
[[PubMed Abstract](#)] -
- Rey D, Piroth L, Wendling MJ, et al. Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): a multicentre, open-label, randomised controlled trial. *Lancet Infect Dis*. 2015;15:1283-91.  
[[PubMed Abstract](#)] -
- Saco TV, Strauss AT, Ledford DK. Hepatitis B vaccine nonresponders: Possible mechanisms and solutions. *Ann Allergy Asthma Immunol*. 2018;121:320-327.  
[[PubMed Abstract](#)] -
- Shafran SD, Mashinter LD, Lindemulder A, Taylor GD, Chiu I. Poor efficacy of intradermal administration of recombinant hepatitis B virus immunization in HIV-infected individuals who fail to respond to intramuscular administration of hepatitis B virus vaccine. *HIV Med*. 2007;8:295-9.  
[[PubMed Abstract](#)] -
- Splawn LM, Bailey CA, Medina JP, Cho JC. Heplisav-B vaccination for the prevention of hepatitis B virus



infection in adults in the United States. *Drugs Today (Barc)*. 2018;54:399-405.


[\[PubMed Abstract\]](#) -

- van den Berg R, van Hoogstraten I, van Agtmael M. Non-responsiveness to hepatitis B vaccination in HIV seropositive patients; possible causes and solutions. *AIDS Rev*. 2009;11:157-64.  
[\[PubMed Abstract\]](#) -
- Van Den Ende C, Marano C, Van Ahee A, Bunge EM, De Moerlooze L. The immunogenicity and safety of GSK's recombinant hepatitis B vaccine in adults: a systematic review of 30 years of experience. *Expert Rev Vaccines*. 2017;16:811-32.  
[\[PubMed Abstract\]](#) -
- Vesikari T, Langley JM, Segall N, et al. Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial. *Lancet Infect Dis*. 2021;21:1271-81.  
[\[PubMed Abstract\]](#) -
- Walayat S, Ahmed Z, Martin D, Puli S, Cashman M, Dhillon S. Recent advances in vaccination of non-responders to standard dose hepatitis B virus vaccine. *World J Hepatol*. 2015;7:2503-9.  
[\[PubMed Abstract\]](#) -
- Yousaf F, Gandham S, Galler M, Spinowitz B, Charytan C. Systematic review of the efficacy and safety of intradermal versus intramuscular hepatitis B vaccination in end-stage renal disease population unresponsive to primary vaccination series. *Ren Fail*. 2015;37:1080-8.  
[\[PubMed Abstract\]](#) -
- Zuckerman JN, Sabin C, Craig FM, Williams A, Zuckerman AJ. Immune response to a new hepatitis B vaccine in healthcare workers who had not responded to standard vaccine: randomised double blind dose-response study. *BMJ*. 1997;314:329-33.  
[\[PubMed Abstract\]](#) -

# Figures

**Figure 1 History of Hepatitis B Vaccines Licensed in the United States**


Image source: David H. Spach, MD



**Figure 2 Estimated Proportion of Adults\* who Received Hepatitis B Vaccine, National Health Interview Survey, 2018-2019**


\*Adults = 19 years of age and older

Source: Lu PJ, Hung MC, Srivastav A, et al. Surveillance of Vaccination Coverage Among Adult Populations -United States, 2018. MMWR Surveill Summ. 2021;70:1-26.



### Figure 3 HBV Vaccine Recommendations in United States


Source: Weng MK, Doshani M, Khan MA, et al. Universal Hepatitis B Vaccination in Adults Aged 19-59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:477-83.



**Figure 4 Recommended Hepatitis B Vaccine Schedule in Adults**


\*Before a potential exposure, such as travel, Twinrix can be administered as an accelerated series at days 1, 7, 21-30, followed by a fourth dose at 12 months.

Modified from: Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018;67:1-31.




**Figure 5 Recommended Hepatitis B Vaccine Schedule in Children**

Source: Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018;67:1-31.



**Figure 6 Dosing and Schedule of Hepatitis B Vaccines in Persons Receiving Hemodialysis**

Source: Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018;67:1-31.




### Figure 7 Recommended Hepatitis B Immunization In Persons with HIV

Note: A 1.0 mL dose of *Twinrix* contains 720 ELISA units of inactivated hepatitis A virus (antigen component from Havrix) and 20 µg HBsAg (antigen component from Engerix-B). *Twinrix* can be given on an accelerated schedule, but the accelerated schedule requires a total of 4 doses (days 0, 7, and 21 to 30) followed by a booster dose at 12 months).

Rating System for Prevention and Treatment Recommendations. A: Strong recommendation for the statement; B: Moderate recommendation for the statement; C: Optional recommendation for the statement; I: One or more randomized trials with clinical outcomes and/or validated laboratory endpoints; II: One or more well-designed, non-randomized trials or observational cohort studies with long-term clinical outcomes; III: Expert opinion


Source: Panel on Opportunistic Infections in Adults and Adolescents with HIV. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Hepatitis B virus infection. Last Updated: December 16, 2024.






**Figure 8 (Image Series) - Minimal Acceptable Dosing Intervals for Hepatitis B Vaccines (Image Series) - Figure 8 (Image Series) - Minimal Acceptable Dosing Intervals for Hepatitis B Vaccines**  
**Image 8A: Engerix-B: Minimal Acceptable Dosing Intervals**

Doses administered up to 4 days before the minimal acceptable dosing intervals are valid, but doses administered 5 or more days before the minimum dosing interval must be repeated using the correct schedule.




**Figure 8 (Image Series) - Minimal Acceptable Dosing Intervals for Hepatitis B Vaccines**  
**Image 8B: Heplisav-B: Minimal Acceptable Dosing Intervals**

Doses administered up to 4 days before the minimal acceptable dosing intervals are valid, but doses administered 5 or more days before the minimum dosing interval must be repeated using the correct schedule.



**Figure 8 (Image Series) - Minimal Acceptable Dosing Intervals for Hepatitis B Vaccines**  
**Image 8C: Recombivax-HB: Minimal Acceptable Dosing Intervals**


Doses administered up to 4 days before the minimal acceptable dosing intervals are valid, but doses administered 5 or more days before the minimum dosing interval must be repeated using the correct schedule.



**Figure 9 Heplisav-B Vaccine versus Engerix-B Vaccine in Healthy Adults 18-55 Years of Age**

In this trial, the primary endpoint was the percentage of persons who achieved seroprotection 8 weeks after the final dose of the Heplisav-B vaccine series or 4 weeks after completing the Engerix-B vaccine series. Seroprotection was defined as an anti-HBs titer of at least 10 mIU/mL.


Source: Halperin SA, Ward B, Cooper C, et al. Comparison of safety and immunogenicity of two doses of investigational hepatitis B virus surface antigen co-administered with an immunostimulatory phosphorothioate oligodeoxyribonucleotide and three doses of a licensed hepatitis B vaccine in healthy adults 18-55 years of age. *Vaccine*. 2012;30:2556-63.



**Figure 10 Heplisav-B Vaccine versus Engerix-B Vaccine in Healthy Adults 40-70 Years of Age**

In this trial, the primary endpoint was the percentage of persons who achieved seroprotection 8 weeks after the final dose of the vaccine series. Seroprotection was defined as an anti-HBs titer of at least 10 mIU/mL.

Source: Heyward WL, Kyle M, Blumenau J, et al. Immunogenicity and safety of an investigational hepatitis B vaccine with a Toll-like receptor 9 agonist adjuvant (HBsAg-1018) compared to a licensed hepatitis B vaccine in healthy adults 40-70 years of age. *Vaccine*. 2013;31:5300-5.



**Figure 11 Recommended Approach to Infants (Born to HBsAg-Positive Mothers) Who Do Not Respond to HBV Vaccine**


\*For infants born to HBsAg-positive mothers, anti-HBs and HBsAg testing should be performed at least 1 month after final hepatitis B vaccine dose and 9 months after receipt of hepatitis B immune globulin (HBIG).  
 ^The two additional doses should be given on regular vaccine schedule to complete the second HBV vaccine series.

§If anti-HBs remains <10 mIU/mL after repeat vaccination, there is no evidence for benefit of giving additional vaccine doses.

Some experts recommend an alternative strategy of giving a second complete series (instead of the one initial dose of hepatitis B vaccine), followed by anti-HBs testing 1-2 months after the final dose.

Source: Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018;67:1-31.

**Approach to Vaccine Nonresponders  
 Infants Born to HBsAg+ Mothers**




**Figure 12 Approach to Health Care Workers Who Do Not Respond to HBV Vaccine**

^For occupational exposures to hepatitis B, no action for hepatitis B prophylaxis (regardless of source patient hepatitis B surface antigen status).

\*Health care workers should receive evaluation for all occupational exposures to hepatitis B. Some experts recommend a more practical alternative strategy for very recently vaccinated health care workers with anti-HBs less than 10 mIU/mL that consists of giving a second complete series (instead of the one initial dose of hepatitis B vaccine), followed by anti-HBs testing 1-2 months after the final dose.

Source: Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018;67:1-31.

## Approach to Vaccine Nonresponders Health Care Workers




**Figure 13 Approach to Immunocompromised Hosts Who Do Not Respond to HBV Vaccine**

For persons with HIV who do not respond to the initial hepatitis B vaccine series, some experts recommend administering four doses of double-dose vaccine at 0, 1, 2, and 6 months

Source: Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018;67:1-31.

**Approach to HBV Vaccine Nonresponders  
Immunocompromised Hosts**





**Figure 14 Approach to Hemodialysis Patients Who Do Not Respond to HBV Vaccine**

This graphic describes the approach to hemodialysis patients who do not respond to the initial HBV vaccine series.

^For adults, the repeat hepatitis B vaccine series should consist of the high-dose (40 µg per dose) HBsAg given as the 3-dose series for Recombivax-HB or 4 doses for Engerix-B.

\*For persons who respond to the repeat vaccine series and have an anti-HBs titer of 10 mIU/mL or greater, annual testing for anti-HBs is recommended, with administration of a booster dose of hepatitis B vaccine if the anti-HBs titer is less than 10 mIU/mL.

Source: Centers for Disease Control and Prevention. Guidelines for Vaccinating Kidney Dialysis Patients and Patients with Chronic Kidney Disease. December 2012.




Table 1.
<b>Indications for Hepatitis B Vaccination</b>
Groups with Indication for Hepatitis B Vaccination
All infants
Unvaccinated Children Younger than 19 Years of Age
Adults 19 to 59 Years of Age
Adults 60 Years of Age and Older with Risk Factors for Hepatitis B
<ul style="list-style-type: none"> <li>• Persons at Risk for HBV Infection by Sexual Exposure               <ul style="list-style-type: none"> <li>◦ Sex partners of HBsAg-positive persons</li> <li>◦ Sexually active persons who are not in a long-term, mutually monogamous relationship (e.g. persons with more than one sex partner during the previous 6 months)</li> <li>◦ Persons seeking evaluation or treatment for a sexually transmitted infection</li> <li>◦ Men who have sex with men</li> </ul> </li> <li>• Persons at Risk for Infection by Percutaneous Exposure               <ul style="list-style-type: none"> <li>◦ Persons who currently or recently injected drugs</li> <li>◦ Household contacts of HBsAg-positive persons</li> <li>◦ Residents and staff of facilities for developmentally disabled persons</li> <li>◦ Health care and public safety personnel with reasonably anticipated risk for exposure to blood or blood-contaminated body fluids</li> <li>◦ Hemodialysis, predialysis, peritoneal dialysis, and home dialysis patients</li> <li>◦ Persons with diabetes aged 19-59 years of age</li> <li>◦ Persons with diabetes 60 years of age and older at the discretion of the treating clinician</li> </ul> </li> <li>• Others at Increased Risk of Acquiring HBV Infection               <ul style="list-style-type: none"> <li>◦ International travelers to countries with high or intermediate levels of endemic HBV infection (HBsAg prevalence of 2% or greater)</li> <li>◦ Persons with hepatitis C virus infection</li> <li>◦ Persons with chronic liver disease (including, but not limited to, persons with cirrhosis, fatty liver disease, alcoholic liver disease, autoimmune hepatitis, and an ALT or AST level greater than twice the upper limit of normal)</li> <li>◦ Persons with HIV infection</li> <li>◦ Incarcerated persons</li> </ul> </li> </ul>
Adults 60 years of age and older without known risk factors may receive hepatitis B immunization
Abbreviations: ACIP = Advisory Committee on Immunization Practices; HBsAg = hepatitis B surface antigen; HBV = hepatitis B virus; ALT = alanine aminotransferase; AST = aspartate aminotransferase

Source:

- Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018;67:1-31. [[PubMed Abstract](#)]
- Weng MK, Doshani M, Khan MA, et al. Universal Hepatitis B Vaccination in Adults Aged 19-59 Years: Updated Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. MMWR Morb Mortal Wkly Rep. 2022;71:477-83. [[PubMed Abstract](#)]

Table 2.

**Global Prevalence of Chronic HBV Infection, by Country**

<b>Prevalence Category</b>	<b>Country</b>
<b>High</b> (≥8%)	Angola, Cabo Verde, Central African Republic, Chad, Eswatini, Ghana, Guinea, Guinea-Bissau, Kiribati, Lesotho, Liberia, Mali, Mauritania, Niger, Nigeria, Philippines, Sao Tome and Principe, Sierra Leone, Solomon Islands, Taiwan, Timor-Leste, Togo, Tonga, Turkmenistan, Tuvalu, and Zimbabwe.
<b>Intermediate</b> (5.0-7.9%)	Albania, Benin, Burkina Faso, Cameroon, China, Côte d'Ivoire, Democratic People's Republic of Korea, Djibouti, Eritrea, Ethiopia, Federated States of Micronesia, Gabon, Indonesia, Kyrgyzstan, Moldova, Mongolia, Mozambique, Myanmar, Papua New Guinea, Senegal, Somalia, South Sudan, Syria, Tajikistan, Uzbekistan, Vanuatu, and Vietnam.
<b>Low Intermediate</b> (2.0-4.9%)	Afghanistan, Azerbaijan, Bangladesh, Belarus, Bosnia and Herzegovina, Bulgaria, Burundi, Cambodia, Comoros, Congo, Democratic Republic of Congo, Gambia, Georgia, Guyana, Haiti, Hong Kong, India, Iraq, Jamaica, Jordan, Kazakhstan, South Korea, Laos, Madagascar, Malawi, Malaysia, Marshall Islands, Oman, Pakistan, Romania, Rwanda, Samoa, Singapore, South Africa, Sri Lanka, Sudan, Tanzania, Thailand, Trinidad and Tobago, Tunisia, Turkey, Uganda, Yemen, and Zambia.
<b>Low</b>	Algeria, Argentina,

**Prevalence Category** Country

(≤1.9%)

Armenia, Australia, Austria, Bahrain, Belgium, Belize, Bhutan, Bolivia, Brazil, Canada, Chile, Colombia, Costa Rica, Croatia, Cuba, Czechia, Denmark, Dominican Republic, Ecuador, Egypt, El Salvador, Estonia, Fiji, Finland, France, Germany, Greece, Guatemala, Honduras, Hungary, Iran, Ireland, Israel, Italy, Japan, Kenya, Kosovo, Kuwait, Lebanon, Libya, Mexico, Morocco, Nepal, Netherlands, New Zealand, Nicaragua, Norway, Palestine, Panama, Paraguay, Peru, Poland, Portugal, Qatar, Russia, Saudi Arabia, Slovakia, Slovenia, Spain, Suriname, Sweden, Switzerland, Ukraine, United Arab Emirates, United Kingdom, United States, and Venezuela.

**Unknown prevalence (data not available)**

American Samoa, Andorra, Anguilla, Antigua and Barbuda, Aruba, Bahamas, Barbados, Bermuda, Bonaire Sint Eustatius and Saba, Botswana, British Virgin Islands, Brunei, Cayman Islands, Cook Islands, Curaçao, Cyprus, Dominica, Equatorial Guinea, Falkland Islands, Faroe Islands, French Guiana, French Polynesia, Gibraltar, Greenland, Grenada, Guadeloupe, Guam, Holy See, Iceland, Isle of Man, Latvia, Liechtenstein, Lithuania, Luxembourg, Macao, Macedonia, Maldives, Malta, Martinique, Mauritius, Mayotte, Monaco, Montenegro, Montserrat, Namibia,

**Prevalence Category**    Country

Nauru, New Caledonia,  
Niue, Northern Mariana  
Islands, Palau, Puerto Rico,  
Réunion, Saint Barthélemy,  
Saint Helena, Saint Kitts  
and Nevis, Saint Lucia,  
Saint Martin, Saint Pierre  
and Miquelon, Saint  
Vincent and the  
Grenadines, San Marino,  
Serbia, Seychelles, Sint  
Maarten, Tokelau, Turks  
and Caicos Islands, U.S.  
Virgin Islands, Uruguay,  
Wallis and Futuna, and  
Western Sahara.

**NOTE:** This table is based on data from the Centers for Disease Control and Prevention (CDC)  
Source:

- Conners EE, Panagiotakopoulos L, Hofmeister MG, et al. Screening and Testing for Hepatitis B Virus Infection: CDC Recommendations - United States, 2023. MMWR Recomm Rep. 2023;72:1-25. [[PubMed Abstract](#)]

Table 3.

**Hepatitis B Vaccine Schedules for Infants**

		Single-Antigen Vaccine		Single-Antigen + Combination Vaccine <sup>^</sup>	
Maternal HBsAg Status		Dose	Age	Dose	Age
<b>Birth-weight ≥2,000 grams</b>					
	Positive	1 HBIG <sup>§</sup>	Birth (≤12 hours)	1 HBIG	Birth (≤12 hours)
		2	Birth (≤12 hours)	2	Birth (≤12 hours)
		3	1-2 months	3	2 months
			6 months <sup>¶</sup>	4	4 months
					6 months <sup>¶</sup>
	Unknown*	1	Birth (≤12 hours)	1	Birth (≤12 hours)
		2	1-2 months	2	2 months
		3	6 months <sup>¶</sup>	3	4 months
				4	6 months <sup>¶</sup>
	Negative	1	Birth (≤24 hours)	1	Birth (≤24 hours)
		2	1-2 months	2	2 months
		3	6-18 months <sup>¶</sup>	3	4 months
				4	6 months <sup>¶</sup>
<b>Birth-weight &lt;2,000 grams</b>					
	Positive	1 HBIG	Birth (≤12 hours)	1 HBIG	Birth (≤12 hours)
		2	Birth (≤12 hours)	2	Birth (≤12 hours)
		3	1 month	3	2 months
		4	2-3 months	4	4 months
			6 months <sup>¶</sup>		6 months <sup>¶</sup>
	Unknown	1 HBIG	Birth (≤12 hours)	1 HBIG	Birth (≤12 hours)
		2	Birth (≤12 hours)	2	Birth (≤12 hours)
		3	1 month	3	2 months
		4	2-3 months	4	4 months
			6 months <sup>¶</sup>		6 months <sup>¶</sup>
	Negative	1	Hospital	1	Hospital
		2	Discharge or Age	2	Discharge or Age
		3	1 month	3	1 month
			2 months	4	2 months
			6-18 months <sup>¶</sup>		4 months
					6 months <sup>¶</sup>

**Abbreviations:** HBsAg = hepatitis B surface antigen; HBIG = hepatitis B immune globulin  
<sup>\*</sup>Mothers should have blood drawn and tested for HBsAg as soon as possible after admission for delivery; if the mother is found to be HBsAg positive, the infant should receive HBIG as soon as possible but no later than age 7 days.  
<sup>^</sup>Pediarix should not be administered before age 6 weeks.  
<sup>§</sup>HBIG should be administered at a separate anatomical site from vaccine.  
<sup>¶</sup>The final dose in the vaccine series should not be administered before age 24 weeks (164 days).

Table 4.

**Recommended Doses of Hepatitis B Vaccine in Children, Adolescents, and Adults<sup>+</sup>**

Age group (years)	Single-Antigen Vaccines						Combination Vaccines			
	Recombivax-HB		Engerix-B		Heplisav-B <sup>^</sup>		Pediarix <sup>*</sup>		Twinrix <sup>†</sup>	
	Dose (µg)	Vol (mL)	Dose	Vol (mL)	Dose (µg)	Vol (mL)	Dose (µg)	Vol (mL)	Dose	Volume
<b>Standard Dosing</b>										
Birth through 10	5	0.5	10	0.5	N/A	N/A	10 <sup>*</sup>	0.5	N/A	N/A
11 through 15	10 <sup>§</sup>	1.0	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
11 through 19	5	0.5	10	0.5	N/A	N/A	N/A	N/A	N/A	N/A
≥20	10	1.0	20	1.0	20	0.5	N/A	N/A	20 <sup>†</sup>	1.0
<b>Dosing in Hemodialysis Patients and Other Immunocompromised Persons</b>										
<20	5	0.5	10	0.5	N/A	N/A	N/A	N/A	N/A	N/A
≥20	40 <sup>#</sup>	1.0 <sup>#</sup>	40	2.0	N/A	N/A	N/A	N/A	N/A	N/A

<sup>+</sup> **Note:** this table is modified from original to include information on Heplisav-B

**Abbreviation:** N/A = not applicable (not approved for use).

<sup>^</sup> Heplisav-B is approved for use in persons aged ≥18; each dose also includes 3,000 µg of CpG 1018 adjuvant

<sup>\*</sup> Pediarix is approved for use in persons aged 6 weeks through 6 years (prior to the 7th birthday).

<sup>†</sup> Twinrix is approved for use in persons aged ≥18 years.

<sup>§</sup> The adult formulation approved for ages 11 through 15 and is administered on a 2-dose schedule.

<sup>#</sup> The Recombivax-HB Dialysis Formulation has 40 µg of HBsAg per 1 mL

Source:

- Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018;67:1-31. [[PubMed Abstract](#)]

Table 5.

**Conditions Associated with Decreased Response to HBV Vaccine**

• Age older than 40 years
• Male sex
• Obesity
• Diabetes mellitus
• Tobacco smoking
• Chronic hepatitis C infection
• Alcohol use disorder
• Chronic kidney disease
• HIV infection
• Celiac disease
• Other immune compromising conditions

Source:

- Schillie S, Vellozzi C, Reingold A, et al. Prevention of Hepatitis B Virus Infection in the United States: Recommendations of the Advisory Committee on Immunization Practices. MMWR Recomm Rep. 2018;67:1-31. [[PubMed Abstract](#)]



